Comparing the current results to its competitors, Aclaris Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 37.18 % year on year. The sales growth was above Aclaris Therapeutics Inc 's competitors' average revenue growth of 13.7 %, achieved in the same quarter.
Aclaris Therapeutics Inc , slower than the average decrease reported by the company's competitors of -28.3 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -28.3 %
Aclaris Therapeutics Inc 's Comment on Competition and Industry Peers
The company does not have manufacturing facilities and relies on third parties for production. The pharmaceutical industry is highly competitive, with competitors including major pharmaceutical, biotechnology, and specialty pharmaceutical companies, as well as academic institutions and governmental agencies. Competitors developing monoclonal antibodies targeting the TSLP ligand or receptor include Amgen and AstraZeneca (Tezepelumab, AMG-104), KeyMed Biosciences (CM326), Uniquity Bio (solrikitug), Windward Bio, Harbour BioMed, Kelun-Biotech (WIN378/HBM9378), GlaxoSmithKline (GSK) (GSK5784283), Generate Biomedicines (GB-0895), Qyuns Therapeutics (QX008N), and UpStream Bio (verekutig). For ATI-052, competitors developing multi-specific antibodies inhibiting TSLP and IL-4Rα include Innovent Biologics (IBI3002) and Pfizer (PF-07275315). Other competitors developing multi-specific antibodies targeting TSLP, IL-4, and IL-13 include Regeneron Pharmaceuticals and Sanofi (dupilumab), Sanofi (lunsekimig), Pfizer (PF-07264660), and KeyMed Biosciences (CM512). Treatments for atopic dermatitis include biologics, corticosteroids, calcineurin inhibitors, mycophenolate products, JAK inhibitors, antibiotics, and antihistamines. Asthma therapies include controller and reliever medications and biologics from Genentech and Novartis (omalizumab), Sanofi and Regeneron (dupilumab), GSK (mepolizumab, depemokimab), Amgen and AstraZeneca (tezepelumab), and AstraZeneca (benralizumab), with additional products in development.
Strong sales growth of 37.18 % in Overall company contributed to Aclaris Therapeutics Inc increase in total revenue by 37.18 % Aclaris Therapeutics Inc improved its market share in this segment, to approximately 0 %.
September 17, 2024
Aclaris Therapeutics has recently completed a pivotal step in the journey of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, by dosing the first patient in not one, but two Phase 2a clinical trials. These trials aim to evaluate the efficacy of ATI-2138 in treating moderate to severe atopic dermatitis and moderate to severe ulcerative colitis, respectively. The move underscores Aclaris Therapeutics commitment to addressing unmet needs in autoimmune diseases, leveraging their novel therapeutic candidates to potentially transform patient care. ATI-2138: A Breakthrough in Autoimmune Disease Management Mechanism of Action: ATI-2138 is designed to inhibit both ITK (interleukin-2-inducible T-cell ki...
In a pivotal corporate update, Aclaris Therapeutics Inc., a pharmaceutical company specializing in dermatological treatments, provided significant insights into their ongoing efforts and the systemic changes anticipated in their operations. Primarily, the company disclosed its tentative results for the ATI-1777 Phase 2a Trial and news about an unavoidable reduction in its workforce. The company has announced that the results of its ATI-1777 Phase 2a Trial have been published in the esteemed JID Innovations medical journal. ATI-1777 is an innovative topical Janus kinase (JAK) 1/3 inhibitor developed by Aclaris Therapeutics to treat moderate to severe atopic dermatitis. The publication of these trial...
December 5, 2023
Aclaris Therapeutics Partners with Sun Pharma in Patent License Agreement for AlopeciaIn a significant move towards revolutionizing treatment options for alopecia, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a leading clinical-stage biopharmaceutical company, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma) on December 5, 2023.Alopecia, a condition that causes hair loss, has long plagued individuals worldwide, impacting their self-esteem and overall well-being. Aclaris Therapeutics has been at the forefront of developing novel drugs to address immuno-inflammatory diseases, and this strategic collaboration with Sun Pharma marks yet another milestone in their...
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Kymera Therapeutics Inc is a biotechnology company that focuses on developing targeted protein degraders as potential therapeutic solutions. They utilize a proprietary technology platform to design and develop small molecules that can selectively degrade disease-causing proteins, aiming to treat various diseases including cancer and autoimmune disorders.
Sources:
Aclaris Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aclaris Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
